NDAINJECTIONINJECTABLE
Approved
Oct 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURABOLIN (nandrolone phenpropionate) is an injectable anabolic steroid approved by the FDA in 1959 for therapeutic use. The drug functions as an androgen receptor agonist that promotes protein synthesis and anabolic effects. It was historically used in clinical settings for conditions including anemia, wasting syndromes, and certain metabolic disorders.
LOE Approaching
With LOE approaching and minimal linked job activity, this legacy product represents a declining portfolio asset with limited commercial expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DURABOLIN offers minimal career advancement opportunity given its lifecycle status and zero linked job openings. This legacy product represents a sunset portfolio asset with shrinking market relevance and reduced team investment.
Brand Manager (Legacy)Field Sales Representative
Worked on DURABOLIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.